Scranton Richard 4

4 · Pacira BioSciences, Inc. · Filed Jun 5, 2019

Form 4

Period: 2019-06-03

Chief Scientific Officer

Transactions

Exercise/Conversion
Common Stock
2019-06-03$10.52/sh+3,010$31,665→ 23,111 total
Exercise/Conversion
Stock Option (Right to Buy)
2019-06-03−3,010→ 0 total
Exercise: $10.52Exp: 2022-03-02→ Common Stock (3,010 underlying)
Exercise/Conversion
Common Stock
2019-06-03$10.81/sh+12,500$135,125→ 35,611 total
Sale
Common Stock
2019-06-03$43.21/sh−15,510$670,187→ 20,101 total
Exercise/Conversion
Stock Option (Right to Buy)
2019-06-03−12,500→ 0 total
Exercise: $10.81Exp: 2022-06-05→ Common Stock (12,500 underlying)

Footnotes (3)

[F1]The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
[F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $43.14 to $43.49, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F3]The stock options are fully vested.

Documents

1 file